

Elena M Massarotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6434519/publications.pdf>

Version: 2024-02-01

29
papers

3,848
citations

516215

16
h-index

525886

27
g-index

30
all docs

30
docs citations

30
times ranked

5266
citing authors

#	ARTICLE	IF	CITATIONS
1	SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. <i>Science Immunology</i> , 2022, 7, eabf2846.	5.6	31
2	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
3	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , 2021, 3, 116-123.	0.9	5
4	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	2.3	24
5	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 78-88.	2.9	33
6	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
7	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	0.9	43
8	Abstract 15089: Specificity for Inflammatory Pathways and Myocardial Injury Associated With Coronary Microvascular Dysfunction in Rheumatoid Arthritis. <i>Circulation</i> , 2020, 142, .	1.6	1
9	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
10	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
11	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
12	THU0248...UTILITY OF A MOBILE PHONE BASED APPLICATION TO COLLECT PATIENT REPORTED OUTCOME INFORMATION FROM SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
13	237...Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. , 2019, , .		0
14	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000349.	1.1	9
15	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	1.9	15
16	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
17	Mixed-effects association of single cells identifies an expanded effector CD4 ⁺ T cell subset in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	119
18	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. <i>PLoS ONE</i> , 2018, 13, e0200886.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. <i>Nature</i> , 2017, 542, 110-114.	13.7	767
20	Editorial: Interferon- γ Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?. <i>Arthritis and Rheumatology</i> , 2017, 69, 245-248.	2.9	1
21	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. <i>RMD Open</i> , 2016, 2, e000210.	1.8	3
22	Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial. <i>Journal of Rheumatology</i> , 2016, 43, 38-45.	1.0	20
23	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , 2015, 125, 1548-1552.	0.6	170
24	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	1.6	13
25	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056.	1.1	65
26	Hemophagocytic Lymphohistiocytosis: The Partners Healthcare Experience over the Past 8 Years. <i>Blood</i> , 2014, 124, 4104-4104.	0.6	2
27	Marked Hyperferritinemia Does Not Predict for Hemophagocytic Lymphohistiocytosis (HLH) in the Adult Population. <i>Blood</i> , 2014, 124, 4951-4951.	0.6	0
28	To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?. <i>Current Rheumatology Reports</i> , 2011, 13, 317-323.	2.1	3
29	Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. <i>Clinical Therapeutics</i> , 2008, 30, 429-442.	1.1	30